0001279569-23-000998.txt : 20230808 0001279569-23-000998.hdr.sgml : 20230808 20230808071527 ACCESSION NUMBER: 0001279569-23-000998 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESSA Pharma Inc. CENTRAL INDEX KEY: 0001633932 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37410 FILM NUMBER: 231149302 BUSINESS ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: (778) 331-0962 MAIL ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 8-K 1 form8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

—————————

FORM 8-K

—————————

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 8, 2023

—————————

ESSA Pharma Inc.

(Exact name of registrant as specified in its charter)

—————————

British Columbia, Canada

(State or other jurisdiction of incorporation)

001-37410

(Commission File Number)

98-1250703

(IRS Employer Identification No.)

Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada

(Address of principal executive offices)

V5Z 1K5

(Zip Code)

Registrant’s telephone number, including area code: (778) 331-0962

—————————

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	EPIX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The following information is filed pursuant to Item 2.02, “Results of Operations and Financial Condition.”

On August 8, 2023, ESSA Pharma Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.

The information provided under this Item (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01	Financial Statements and Exhibits.

	(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated August 8, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		*ESSA PHARMA INC.*
		(Registrant)


Date: August 8, 2023

	By:	/s/ David Wood
		Name:	David Wood
		Title:	Chief Financial Officer

EX-99.1 2 ex991.htm NEWS RELEASE DATED AUGUST 8, 2023

Exhibit 99.1

ESSA Pharma Provides Corporate Update and Reports Financial Results for

Fiscal Third Quarter Ended June 30, 2023

Completion of the Phase 1 EPI-7386 combination study with Xtandi^®(enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study

Entered into clinical trial support agreement with Janssen to supply Erleada^® (apalutamide) and Zytiga^® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023

Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing

South San Francisco, California and Vancouver, Canada, August 8, 2023 - ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2023. All references to “$” in this release refer to United States dollars, unless otherwise indicated.

“Over the past months we have ramped up preparations to initiate the randomized Phase 2 combination study of EPI-7386 and Astellas and Pfizer’s antiandrogen Xtandi^® (enzalutamide), and we expect to complete the Phase 1 part of the study in the coming quarter,” stated David Parkinson, MD, President and CEO of ESSA. “In the past quarter, we finalized our clinical collaboration with Janssen to evaluate EPI-7386 in combination with Janssen’s antiandrogens Erleada^® (apalutamide) and Zytiga^® (abiraterone acetate) in two Phase 1 cohorts, building on initial Phase 1 clinical data demonstrating promising prostate-specific antigen (“PSA”) declines following combination treatment. ESSA is in a strong cash position as we advance our EPI-7386 studies, with our cash runway expected to fund operations and programs through 2025.”

Clinical and Corporate Highlights for the Third Quarter Ended June 30, 2023

EPI-7386 Clinical Collaborations

·

The Company is preparing to initiate the open-label, randomized Phase 2 study of EPI-7386 and Astellas and Pfizer’s antiandrogen Xtandi^® (enzalutamide) in patients with metastatic castration-resistant prostate cancer (“mCRPC”) naïve to second-generation antiandrogens. The Phase 2 study will assess the anti-tumor activity of EPI-7386 in combination with enzalutamide at the recommended Phase 2 doses versus single agent enzalutamide at the standard-of-care dose. The study is expected to enroll approximately 120 patients. The Company expects to complete the Phase 1 part of the study and establish the recommended Phase 2 combination doses (for both EPI-7386 and enzalutamide when used in combination) in the third calendar quarter of 2023, followed by initiation of the Phase 2 part of the study.

·

In April 2023, the Company entered into a clinical trial support agreement with Janssen Research & Development, LLC (“Janssen”) under which Janssen will supply apalutamide and abiraterone acetate for a Phase 1 clinical study sponsored and conducted by ESSA evaluating EPI-7386 combination therapies in two cohorts. The two cohorts will be evaluated as additional cohorts in the Company’s ongoing Phase 1 study of EPI-7386 (Clinical Trials Identifier: NCT04421222). Cohort 1 will assess EPI-7386 in combination with abiraterone acetate plus prednisone in patients with mCRPC and high-risk metastatic castration-sensitive prostate cancer. Cohort 2 is a Window of Opportunity study in which patients with non-metastatic castration-resistant prostate cancer (“nmCRPC”) will receive up to 12 weeks of single agent EPI-7386 before adding standard-of-care apalutamide. ESSA will retain all rights to EPI-7386. The Company expects enrollment to begin in the second half of calendar 2023.

EPI-7386 Monotherapy

·

The Phase 1b EPI-7386 monotherapy dose expansion study is ongoing and is evaluating two doses/schedules of single agent EPI-7386 in mCRPC patients with less than three prior lines of therapy, no visceral disease and no prior chemotherapy who have progressed on at least one second-generation antiandrogen. The Company is also enrolling nmCRPC patients in the Window of Opportunity cohort of the study, in which patients will receive 12 weeks of EPI-7386 monotherapy treatment before starting standard-of-care therapy.

Corporate Updates

·

In June 2023, the Company announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios.

Summary Financial Results

·

Net Loss. ESSA recorded a comprehensive loss of $7.3 million for the third quarter ended June 30, 2023, compared to a comprehensive loss of $8.8 million for the third quarter ended June 30, 2022. For the third quarter ended June 30, 2023, this included non-cash share-based payments of $1.2 million compared to $1.6 million for the prior year, recognized for stock options granted and vesting. The decrease in the third quarter was primarily attributed to decreases in research and development expenditures and general and administration expenditures in addition to an increase of $1.2 in interest and other income.

·

Research and Development (“R&D”) expenditures. R&D expenditures for the third quarter ended June 30, 2023 were $6.3 million compared to $6.4 million for the third quarter ended June 30, 2022 and include non-cash costs related to share-based payments ($599,621 for the third quarter ended 2023 compared to $872,531 for the third quarter ended 2022). The decrease in R&D expenditures for the year ended June 30, 2023 is the result of decreased non-cash share-based payments, legal patents and license fees and manufacturing costs related to the Phase 1 clinical trial of EPI-7386.

·

General and administration (“G&A”) expenditures. G&A expenditures for the third quarter ended June 30, 2023 were $2.6 million compared to $2.9 million for the third quarter ended June 30, 2022 and include non-cash costs related to share-based payments of $561,452 for the third quarter ended 2023 compared to $718,469 for the third quarter ended 2022. The decrease in the third quarter is the result of decreased non-cash share-based payments, salaries and benefits and consulting and subcontractor fees.

Liquidity and Outstanding Share Capital

At June 30, 2023, the Company had available cash reserves and short-term investments of $152.5 million reflecting the gross proceeds of the February 2021 financing of approximately $150.0 million, less operating expenses in the intervening period. The Company’s cash position is expected to be sufficient to fund current and planned operations through 2025.

As of June 30, 2023, the Company had 44,092,374 common shares issued and outstanding.

In addition, as of June 30, 2023 there were 2,927,477 common shares issuable upon the exercise of warrants and broker warrants. This includes 2,920,000 prefunded warrants at an exercise price of $0.0001, and 7,477 warrants at a weighted average exercise price of $42.80. There were 8,150,274 common shares issuable upon the exercise of outstanding stock options at a weighted-average exercise price of $5.05 per common share.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

Forward-Looking Statement Disclaimer

This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements regarding the completion of the Phase 1 combination study with enzalutamide and initiation of the randomized Phase 2 part of the study, enrollment in the monotherapy and combination studies, the assessment of anti-tumor activity in the Phase 2 combination study, the clinical trial support agreement, the supply of apalutamide and abiraterone acetate, the rights to EPI-7386, the testing of new antiandrogen combinations with EPI-7386, the treatments under Cohort 1 and Cohort 2 of the Phase 1 clinical trial, the Phase 1b dose expansion study and the Window of Opportunity Study, and the Company’s expected cash runway into 2025.

Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA’s actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA’s current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA’s financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions.

Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA’s Annual Report on Form 10-K dated December 13, 2022 under the heading “Risk Factors”, a copy of which is available on ESSA’s profile on EDGAR at www.sec.gov.com and on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on ESSA’s EDGAR and SEDAR profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.

ESSA PHARMA INC.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

(Unaudited)

Amounts in thousands of United States dollars

		June 30, 2023				September 30, 2022

Cash and cash equivalents		$	38,467			$	57,076
Prepaids and other assets			115,183				112,429

Total assets		$	153,650			$	169,505

Current liabilities			3,407				2,310
Long-term debt			—				76
Shareholders' equity			150,243				167,118

Total liabilities and shareholders’ equity		$	153,650			$	169,505

ESSA PHARMA INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

Amounts in thousands of United States dollars, except share and per share data

Three months ended
June 30, 2023 Three months ended
June 30, 2022 Nine months ended
June 30, 2023 Nine months ended
June 30, 2022

OPERATING EXPENSES

Research and development $ 6,271 $ 6,395 $ 16,096 $ 20,064

Financing costs 2 3 6 11

General and administration 2,639 2,896 8,889 9,775

Total operating expenses (8,912 ) (9,294 ) (24,991 ) (29,850 )

Gain on derivative liability — 2 — 20

Interest and other items 1,613 419 3,892 1,005

Net loss before taxes (7,299 ) (8,873 ) (21,099 ) (28,825 )

Income tax expense (recovery) — 46 (2 ) 46

Net loss for the period $ (7,299 ) $ (8,827 ) $ (21,101 ) $ (28,779 )

OTHER COMPREHENSIVE LOSS

Unrealized gain (loss) on short-term investments 43 (3 ) 13 (52 )

Loss and comprehensive loss for the period $ (7,256 ) $ (8,830 ) $ (21,088 ) $ (28,831 )

Basic and diluted loss per common share $ (0.17 ) $ (0.20 ) $ (0.48 ) $ (0.65 )

Weighted average number of
common shares outstanding 44,092,374 44,059,700 44,085,941 44,026,502

Company Contact

David Wood, Chief Financial Officer

ESSA Pharma Inc.

Contact: (778) 330-0962

Email: dwood@essapharma.com

EX-101.SCH 3 epix-20230808.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 epix-20230808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 epix-20230808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 08, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 08, 2023
Entity File Number	001-37410
Entity Registrant Name	ESSA Pharma Inc.
Entity Central Index Key	0001633932
Entity Tax Identification Number	98-1250703
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	Suite 720
Entity Address, Address Line Two	999 West Broadway
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V5Z 1K5
City Area Code	778
Local Phone Number	331-0962
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	EPIX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 form8k_htm.xml IDEA: XBRL DOCUMENT 0001633932 2023-08-08 2023-08-08 iso4217:USD shares iso4217:USD shares 0001633932 false A1 8-K 2023-08-08 ESSA Pharma Inc. 001-37410 98-1250703 Suite 720 999 West Broadway Vancouver BC CA V5Z 1K5 778 331-0962 false false false false Common Shares, no par value EPIX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " M 6\0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #M.0A7)!Z;HJT #X M 0 &@ @ '/$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " #M.0A799!YDAD! #/ P $P @ &T L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #^$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://essapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode - form8k.htm 21 form8k.htm epix-20230808.xsd epix-20230808_lab.xml epix-20230808_pre.xml ex991.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "epix-20230808_lab.xml" ] }, "presentationLink": { "local": [ "epix-20230808_pre.xml" ] }, "schema": { "local": [ "epix-20230808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "EPIX", "nsuri": "http://essapharma.com/20230808", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "AsOf2023-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://essapharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "AsOf2023-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://essapharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001279569-23-000998-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001279569-23-000998-xbrl.zip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